diabetes - GuerillaStockTrading.com https://www.guerillastocktrading.com/tag/diabetes/ Live Free or Die Traying Sun, 25 Aug 2024 20:45:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.1 https://www.guerillastocktrading.com/wp-content/uploads/2020/01/cropped-cropped-dollars-32x32.png diabetes - GuerillaStockTrading.com https://www.guerillastocktrading.com/tag/diabetes/ 32 32 Think GLP-1 drugs are a miracle? Wait until you hear about the hidden risks that nobody’s talking about! 😳 https://www.guerillastocktrading.com/think-glp-1-drugs-are-a-miracle/ Sun, 25 Aug 2024 20:45:07 +0000 https://www.guerillastocktrading.com/?p=378214 GLP-1 receptor agonists, a class of drugs initially developed to manage type 2 diabetes, have recently gained widespread…

This article Think GLP-1 drugs are a miracle? Wait until you hear about the hidden risks that nobody’s talking about! 😳 appeared first on Guerilla Stock Trading.

]]> Could this new class of drugs revolutionize healthcare? How GLP-1 drugs are changing the game 🔄 https://www.guerillastocktrading.com/could-this-new-class-of-drugs-revolutionize-healthcare-how-glp-1-drugs-are-changing-the-game-%f0%9f%94%84/ Sun, 09 Jun 2024 21:12:37 +0000 https://www.guerillastocktrading.com/?p=375516 A groundbreaking new class of drugs has emerged from the laboratories of biopharma companies, promising to revolutionize the…

This article Could this new class of drugs revolutionize healthcare? How GLP-1 drugs are changing the game 🔄 appeared first on Guerilla Stock Trading.

]]> Omnipod 5’s Role in Insulet’s Impressive Q1 Earnings Surge https://www.guerillastocktrading.com/insulet-q1-2024-earnings-call/ Sun, 12 May 2024 00:39:16 +0000 https://www.guerillastocktrading.com/?p=374691 Insulet’s Q1 2024 results have surpassed expectations, driven by strong demand for Omnipod 5, leading to raised revenue…

This article Omnipod 5’s Role in Insulet’s Impressive Q1 Earnings Surge appeared first on Guerilla Stock Trading.

]]> Eli Lilly’s Ambitious Expansion Plan: A Game-Changer for GLP-1 Medicines https://www.guerillastocktrading.com/eli-lillys-ambitious-expansion-plan-a-game-changer-for-glp-1-medicines/ Sat, 04 May 2024 20:36:45 +0000 https://www.guerillastocktrading.com/?p=374319 In a bold move poised to reshape the landscape of diabetes and obesity treatment, Eli Lilly announced its…

This article Eli Lilly’s Ambitious Expansion Plan: A Game-Changer for GLP-1 Medicines appeared first on Guerilla Stock Trading.

]]> The Obesity Drug Revolution: A New Era in Weight Loss Treatment https://www.guerillastocktrading.com/the-obesity-drug-revolution-a-new-era-in-weight-loss-treatment/ Sat, 04 May 2024 20:23:04 +0000 https://www.guerillastocktrading.com/?p=374315 In a groundbreaking clinical trial conducted by Novo Nordisk four years ago, a drug called semaglutide demonstrated remarkable…

This article The Obesity Drug Revolution: A New Era in Weight Loss Treatment appeared first on Guerilla Stock Trading.

]]> Medtronic’s Third Quarter Fiscal 2024 Financial Results https://www.guerillastocktrading.com/medtronics-third-quarter-fiscal-2024-financial-results/ Wed, 21 Feb 2024 03:22:44 +0000 https://www.guerillastocktrading.com/?p=372093 Medtronic (MDT), a global leader in medical technology, recently announced its financial results for the third quarter of…

This article Medtronic’s Third Quarter Fiscal 2024 Financial Results appeared first on Guerilla Stock Trading.

]]> Eli Lilly’s Strong Finish to 2023 https://www.guerillastocktrading.com/eli-lillys-strong-finish-to-2023/ Tue, 06 Feb 2024 16:36:37 +0000 https://www.guerillastocktrading.com/?p=371559 Eli Lilly (LLY), one of the pharmaceutical giants, concluded 2023 on a high note, surpassing analyst expectations with…

This article Eli Lilly’s Strong Finish to 2023 appeared first on Guerilla Stock Trading.

]]> Eli Lilly’s Strong Q4 Performance Driven by Zepbound and Mounjaro https://www.guerillastocktrading.com/eli-lillys-strong-q4-performance-driven-by-zepbound-and-mounjaro/ Tue, 06 Feb 2024 16:20:15 +0000 https://www.guerillastocktrading.com/?p=371555 Eli Lilly, one of the leading pharmaceutical giants, reported impressive fourth-quarter results in 2023, surpassing both revenue and…

This article Eli Lilly’s Strong Q4 Performance Driven by Zepbound and Mounjaro appeared first on Guerilla Stock Trading.

]]> DexCom: A Rising Star in the Diabetes Care Market https://www.guerillastocktrading.com/dexcom-a-rising-star-in-the-diabetes-care-market/ Fri, 02 Feb 2024 02:30:26 +0000 https://www.guerillastocktrading.com/?p=371310 In the realm of medical devices and healthcare innovation, one company stands out with a promising outlook and…

This article DexCom: A Rising Star in the Diabetes Care Market appeared first on Guerilla Stock Trading.

]]> Novo Nordisk’s Stellar Performance Propels ADRs to Record Highs https://www.guerillastocktrading.com/novo-nordisks-stellar-performance-propels-adrs-to-record-highs/ Thu, 01 Feb 2024 04:37:17 +0000 https://www.guerillastocktrading.com/?p=371290 Novo Nordisk (NVO), the Danish pharmaceutical giant renowned for its expertise in weight-loss and diabetes drugs, has set…

This article Novo Nordisk’s Stellar Performance Propels ADRs to Record Highs appeared first on Guerilla Stock Trading.

]]> The Potential Health-Care Sector Comeback: Biotech and Medtech in Focus https://www.guerillastocktrading.com/the-potential-health-care-sector-comeback-biotech-and-medtech-in-focus/ Wed, 17 Jan 2024 14:21:48 +0000 https://www.guerillastocktrading.com/?p=370653 The health-care sector faced a challenging year in 2023, but signs of a comeback are emerging in 2024.…

This article The Potential Health-Care Sector Comeback: Biotech and Medtech in Focus appeared first on Guerilla Stock Trading.

]]> GSBR-1290: A Promising Oral GLP-1 Receptor Agonist in Diabetes and Obesity https://www.guerillastocktrading.com/gsbr-1290-a-promising-oral-glp-1-receptor-agonist-in-diabetes-and-obesity/ Sat, 23 Dec 2023 14:22:43 +0000 https://www.guerillastocktrading.com/?p=369971 Structure Therapeutics (GPCR) has unveiled exciting updates on its development program for GSBR-1290, a highly selective oral GLP-1…

This article GSBR-1290: A Promising Oral GLP-1 Receptor Agonist in Diabetes and Obesity appeared first on Guerilla Stock Trading.

]]>